Invest Securities confirms its Buy rating on OSE Immunotherapeutics shares, with a price target lowered from 10.3 to 8.26 euros.

The analyst reports that on Friday after trading, OSE Immuno announced that it had regained the rights to OSE-127 after Servier decided not to pursue development of this asset following the failure of phase IIa in Sjögren's syndrome.

'As a reminder, in 2016, the two groups had entered into a collaboration to address autoimmune diseases with OSE-127 as part of 2 clinical trials conducted in parallel. Servier had placed a license option on OSE-127, which it has therefore decided not to exercise, thereby cancelling out the potential for an associated milestone of 15mE', says the analyst.

Invest Securities has thus adjusted its model by withdrawing the Sjögren's syndrome program line, but remains positive in view of the potential represented by OSE's entire pipeline.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.